Tdark LYPD6B Ly6/PLAUR domain-containing protein 6B

Protein Summary

Description

Believed to act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity. In vitro acts on nAChRs in a subtype- and stoichiometry-dependent manner. Modulates specifically alpha-3(3):beta-4(2) nAChRs by enhancing the sensitivity to ACh, decreasing ACh-induced maximal current response and increasing the rate of desensitization to ACh; has no effect on alpha-7 homomeric nAChRs; modulates alpha-3(2):alpha-5:beta-4(2) nAChRs in the context of CHRNA5/alpha-5 variant Asn-398 but not its wild-type sequence.

Uniprot Accession IDs

• Q8NI32
• D3DP90
• Q53TK0
• Q7Z747
• Q8IXK7

Gene Name

• LYPD6B

Ensembl ID

• ENST00000409029
• ENSP00000386650
• ENSG00000150556
• ENST00000409642
• ENSP00000387077
• ENST00000409876
• ENSP00000386479

Symbol

• CT116
• LYPD7

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
tissue sample	0.78
PubMedID	0.61
transcription factor binding site profile	0.56
transcription factor	0.55
tissue	0.51

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 9.04   (req: < 5)

Gene RIFs: 3   (req: <= 3)

Antibodies: 26   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 9.04   (req: >= 5)

Gene RIFs: 3   (req: > 3)

Antibodies: 26   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Term: 1

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0